MSI in Circulatory DNA of Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:

A Compare of Microsatellite Instability in Circulatory DNA and Tumor Tissue of Endometrial Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03744962
• Other study ID #: EC-MSI
• Status: Recruiting
• Start date: November 10, 2018
• Est. completion date: December 23, 2020

Study information

• Verified date: November 2018
• Source: Peking Union Medical College Hospital
• Contact: Lei Li, M.D.
• Phone: 13911988831
• Email: lileigh[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer. These data will be used for the study of "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 23, 2020
• Est. primary completion date: December 23, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Confirmed primary endometrial cancer before any surgical or chemotherapy treatment

• Signed an approved informed consents

• Feasible for sampling

Exclusion Criteria:

• Not meeting all of the inclusion criteria

Related Conditions & MeSH terms

• Circulating Tumor Cell
• Colorectal Neoplasms, Hereditary Nonpolyposis
• Endometrial Cancer
• Endometrial Neoplasms
• Lynch Syndrome
• Microsatellite Instability
• Neoplastic Cells, Circulating

Locations

Country	Name	City	State
China	Lei Li	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Lei Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of microsatellite instability	Frequencies of different status of microsatellite instability (high microsatellite instability or microsatellite-stable) in the circulatory tumor DNA and in the tumor tissue	Two years